☆ 4.5 Review

Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease

INFLAMMATORY BOWEL DISEASES (2023)

Related references

Note: Only part of the references are listed.

Editorial Material Gastroenterology & Hepatology

Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease

Nathalie Van Den Berghe et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives

Peter M. Irving et al.

Summary: Therapeutic drug monitoring (TDM) is an optimization strategy in the treatment of inflammatory bowel diseases, aiming to achieve maximal treatment benefits by monitoring drug concentrations. There are variations in optimal drug concentrations based on treatment targets, disease phenotypes, inflammatory burden, and sampling timing. This review discusses the role of TDM in biologic and oral small molecule therapies, the differences between reactive and proactive TDM, and the areas where evidence is lacking. Future adaptations in TDM usage may contribute to personalized treatment for patients with IBD.

GASTROENTEROLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study

William J. Sandborn et al.

Summary: In this study, Guselkumab demonstrated efficacy and safety in patients with moderately to severely active Crohn's disease, with all three dose regimens showing significant clinical and endoscopic improvements compared to placebo at week 12.

GASTROENTEROLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinumab Therapeutic Drug Monitoring-Impact on Clinical Practice: A Multicenter Cross-Sectional Observational Trial

Waqqas Afif et al.

Summary: In consecutive CD patients treated with UST, the addition of TDM into routine clinical practice did not significantly impact clinical decisions and there was no association between short-term clinical outcomes and serum [UST]. Further studies are warranted before clinicians routinely implement UST TDM into clinical practice.

DIGESTIVE DISEASES AND SCIENCES (2022)

Add to Collection

Article Gastroenterology & Hepatology

Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease

Yushan Pan et al.

Summary: Data on therapeutic drug monitoring in postoperative Crohn's disease are limited. This study found that higher concentrations of tumor necrosis factor antagonists were associated with improved outcomes, while ustekinumab concentrations did not show a relationship with outcomes.

INFLAMMATORY BOWEL DISEASES (2022)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

Maria T. Abreu et al.

Summary: The study confirms the efficacy of ustekinumab in treating patients with ulcerative colitis for up to 3 years, and no new safety issues were observed.

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease

Jacob E. Ollech et al.

Summary: Shortening the ustekinumab dose interval to 4 weeks improved clinical and biological indices of disease activity in patients with Crohn's disease who did not respond to the standard dose every 8 weeks. This approach could be effective and safe for patients who lose response to the standard dose of ustekinumab.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission

Jurij Hanzel et al.

Summary: This study found that serum concentrations of ustekinumab as early as 1 hour after intravenous infusion may be used to identify patients with Crohn's disease most likely to achieve endoscopic remission, which could optimize CD treatment.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study

Jia-yin Yao et al.

Summary: UST is a promising treatment option for refractory Crohn's disease, with an optimal trough concentration above 1.12 μg/mL associated with endoscopic remission at week 16/20 after initiation. Therapeutic monitoring based on drug concentration is crucial for maintaining treatment efficacy in patients.

BMC GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinumab induction concentrations are associated with clinical and biochemical outcomes at week 12 of treatment in Crohn's disease

Margaret Walshe et al.

Summary: The study found that ustekinumab levels at week 6 are significantly associated with baseline Crohn's disease biomarkers and subsequent clinical and biochemical outcomes.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn's disease patients in Finland

Taina Sipponen et al.

Summary: The study highlights the importance of optimizing ustekinumab dosing for refractory Crohn's disease (CD) patients. Nearly a third of CD patients required dose intensification, with higher baseline C-reactive protein (CRP) levels potentially serving as a predictive indicator for dose adjustment.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2021)

Add to Collection

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)

Tadakazu Hisamatsu et al.

Summary: The study evaluated the efficacy and safety of ustekinumab in the East-Asian population with moderate to severely active ulcerative colitis. Results showed that ustekinumab induction and maintenance treatments were effective in East-Asian patients with consistent safety profiles compared to the overall population.

INTESTINAL RESEARCH (2021)

Add to Collection

Article Gastroenterology & Hepatology

Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease

Kento Takenaka et al.

Summary: Studies have shown that cytokine blocker treatment is less effective for small bowel inflammation compared to colonic inflammation, requiring higher serum concentrations to achieve endoscopic remission of small bowel lesions.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Review Gastroenterology & Hepatology

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease

Adam S. Cheifetz et al.

Summary: This study utilized a modified Delphi method to develop a consensus statement regarding the clinical utility of TDM for biologics in IBD, focusing on both reactive and proactive TDM. The results suggest the importance of using reactive TDM to enhance the efficacy of biologics, as well as the recommendation for regular proactive TDM during maintenance therapy.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's disease

Jurij Hanzel et al.

Summary: This study aimed to investigate the effects of ustekinumab dose escalation to every 4 weeks on endoscopic remission and biomarker normalization in patients with Crohn's disease. Results showed that patients with higher ustekinumab concentrations after dose escalation were more likely to achieve endoscopic remission and biomarker normalization.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study

Joel R. Rosh et al.

Summary: The study evaluated the pharmacokinetics, safety, and efficacy of ustekinumab in children with moderately to severely active Crohn's disease. It was found that serum ustekinumab concentrations were lower in patients <40 kg compared to those >= 40 kg. Some patients experienced adverse events during treatment, indicating a need for different dosing regimens.

JOURNAL OF CROHNS & COLITIS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification

Rahul S. Dalal et al.

Summary: Perianal disease, Harvey-Bradshaw Index, current opioid use, and current corticosteroid use are associated with ustekinumab failure after dose intensification in CD patients.

INFLAMMATORY BOWEL DISEASES (2021)

Add to Collection

Article Gastroenterology & Hepatology

One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study

Jasbir Dhaliwal et al.

Summary: The study monitored the efficacy and drug concentration of ustekinumab in adolescent ulcerative colitis patients, with 44% achieving steroid-free remission at 52 weeks, and 1 in 7 meeting the criteria for endoscopic improvement.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Gastroenterology & Hepatology

IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease

Stephen B. Hanauer et al.

JOURNAL OF CROHNS & COLITIS (2020)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease

Claire Painchart et al.

DIGESTIVE DISEASES AND SCIENCES (2020)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis

Omoniyi J. Adedokun et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

P346 Single-centre experience of ustekinumab: Therapeutic drug monitoring in Crohn’s disease patients

C Liefferinckx et al.

Journal of Crohns & Colitis (2020)

Add to Collection

Article Gastroenterology & Hepatology

Clinical relevance of innovative immunoassays for serum ustekinumab and anti-ustekinumab antibody levels in Crohn's disease

Yasuhiro Morita et al.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinumab serum concentrations are associated with clinical outcomes in Crohn's disease - a regional multi-center pilot study

Anne Kerstin Thomann et al.

ZEITSCHRIFT FUR GASTROENTEROLOGIE (2020)

Add to Collection

Article Gastroenterology & Hepatology

Sa1870 USTEKINUMAB LEVELS DIFFERENTIATE PATIENTS WITH ENDOSCOPICALLY ACTIVE AND INACTIVE CROHN'S DISEASE AS DEFINED USING A SERUM BASED ENDOSCOPIC HEALING INDEX

Margaret Walshe et al.

GASTROENTEROLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

S0879 Improved Remission with Proactive Therapeutic Drug Monitoring of Ustekinumab for Crohn’s Disease

Omer Shahab et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)

Add to Collection

Letter Gastroenterology & Hepatology

Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease

Ninon Soufflet et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

REAL WORLD EXPERIENCE IN THERAPEUTIC DRUG MONITORING IN INFLAMMATORY BOWEL DISEASE PATIENTS ON USTEKINUMAB

Kerri Glassner et al.

INFLAMMATORY BOWEL DISEASES (2019)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates

Bram Verstockt et al.

JOURNAL OF CROHNS & COLITIS (2019)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Ustekinumab therapeutic drug monitoring in Crohn's disease patients with loss of response

V. Heron et al.

JOURNAL OF CROHNS & COLITIS (2019)

Add to Collection

Article Gastroenterology & Hepatology

Mo1919 – Ustekinumab Efficiency As a Higher-Line Therapy in Association with Serum Levels in Patients with Crohn’s Disease

Martin Kolar et al.

GASTROENTEROLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center

Judy R. Dayan et al.

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2019)

Add to Collection

Article Gastroenterology & Hepatology

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

W. J. Sandborn et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)

Add to Collection

Article Gastroenterology & Hepatology

Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study

C. R. Rowan et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)

Add to Collection

Article Gastroenterology & Hepatology

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease

Omoniyi J. Adedokun et al.

GASTROENTEROLOGY (2018)

Add to Collection

Review Health Care Sciences & Services

Recommendations for assessing the risk of bias in systematic reviews of health-care interventions

Meera Viswanathan et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2018)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

TROUGH LEVELS AND ANTIBODIES TO USTEKINUMAB ARE NOT CORRELATED TO RESPONSE TO USTEKINUMAB TREATMENT IN CROHN'S DISEASE PATIENTS

Painchart Claire et al.

GASTROENTEROLOGY (2017)

Add to Collection

Article Health Care Sciences & Services

The GRADE Working Group clarifies the construct of certainty of evidence

Monica Hultcrantz et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2017)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Association of Ustekinumab Concentrations Using Anser® UST Mobility Shift Assay and Clinical Response in Crohn's Disease

Brigid S. Boland et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)

Add to Collection

Article Biochemical Research Methods

Ultrasensitive and rapid immuno-detection of human IgE anti-therapeutic horse sera using an electrochemical immunosensor

Isis C. Prado et al.

ANALYTICAL BIOCHEMISTRY (2017)

Add to Collection

Article Gastroenterology & Hepatology

Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease

Robert Battat et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease

B. G. Feagan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Gastroenterology & Hepatology

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

Niels Vande Casteele et al.

GASTROENTEROLOGY (2015)

Add to Collection

Article Gastroenterology & Hepatology

Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis

Lennard Y. W. Lee et al.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2012)

Add to Collection

Article Gastroenterology & Hepatology

A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

William J. Sandborn et al.

GASTROENTEROLOGY (2008)

Add to Collection

Article Education & Educational Research

Bias and efficiency of meta-analytic variance estimators in the random-effects model

W Viechtbauer

JOURNAL OF EDUCATIONAL AND BEHAVIORAL STATISTICS (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.